ClinicalTrials.gg
RecruitingNCT07741877'SARATOGA'Updated Oct 9, 2026

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma

A Phase 2 interventional study of Lifileucel in Sarcoma, Soft Tissue Sarcoma (STS) and Advanced Soft Tissue Sarcoma, sponsored by Iovance Biotherapeutics, Inc.. Recruiting at 2 sites in United States. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Primary conditionLiposarcomaRegistry: SarcomaReclassifiedWhy we changed it
Registry
Sarcoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Liposarcoma
Why
  1. The study's listed conditions name Liposarcoma, a narrower term within Sarcoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Iovance Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 9, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Liposarcoma with a site in United States — 23 open to participants now, 36 under way, 5 of them phase 3. Liposarcoma · United States.

Planned enrollment
28th of 92
80 · median 44
Started
2026
with 3 others
Phase 2
43 of 101
3 open now
Primary completion
2033-09
later than 34 of 35 live
Registered
100th of 101
by date

Among the 101 studies in Liposarcoma with a site in United States, this one is the 28th largest by planned enrollment of the 92 interventional ones that give a count, is one of 4 that started in 2026, is one of 43 in phase 2, reaches primary completion later than 34 of the 35 other live ones, and was the 100th registered.

Liposarcoma

160 studies on the registry are indexed under Liposarcoma; 36 are open to participants now.

Browse Liposarcoma studies →

Open to participants now

23 of the 101 studies in Liposarcoma with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Liposarcoma studies recruiting now, 20 (69%) set no upper age limit and 8 (28%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Liposarcoma with a site in United States, or all of them as a file.
02

Study summary

A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced soft tissue sarcoma ('SARATOGA')

Read the detailed description

The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated soft tissue sarcoma. The length of the study for each participant may be up to 5 calendar years after receiving lifileucel. After Screening, each participant will have surgery to remove some tumor pieces that will be used to make the lifileucel, followed by a baseline visit prior to study treatment. Participants will then receive the lifileucel treatment regimen. This includes 2 drugs (cyclophosphamide and fludarabine) for up to 5 days to decrease lymphocytes in the body, the lifileucel infusion (1 day), and up to 4 days of aldesleukin to boost the activity of the lifileucel. Study visits will be every 6 weeks for 6 months, then every 3 months until 5 calendar years after the lifileucel infusion.

03

Conditions studied

  • Sarcoma
  • Soft Tissue Sarcoma (STS)
  • Advanced Soft Tissue Sarcoma
  • Undifferentiated Pleomorphic Sarcoma (UPS)
  • Dedifferentiated Liposarcoma (DDLPS)

Browse trials for

Keywords

  • TIL
  • Tumor Infiltrating Lymphocytes
  • Cell Therapy
  • Cellular Immuno-therapy
  • IL2
  • Lifileucel
  • Sarcoma
  • Soft Tissue Sarcoma
  • Advanced Soft Tissue Sarcoma
  • LN-145
  • Non-myeloablative lymphodepletion (NMALD)
  • SARATOGA
  • Undifferentiated pleomorphic sarcoma (UPS)
  • Dedifferentiated liposarcoma (DDLPS)
04

In context

Liposarcoma Reclassified

160 studies on the registry are indexed under Liposarcoma; 36 are open to participants now.

This study's planned enrollment of 80 is above the median of 52 across 136 interventional studies indexed under Liposarcoma.

Browse Liposarcoma studies →

Lead sponsor

Iovance Biotherapeutics, Inc. is the lead sponsor of 16 studies on the registry; 8 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Compared within Liposarcoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sarcoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 16 years of age at the time of signing the and assent.
  • Participants who are > 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
  • Participant must have a confirmed diagnosis of confirmed unresectable or UPS (Cohort 1) or DDLPS (Cohort 2), with or without a well-differentiated component, who have received ≥ 1 and a maximum of 3 prior systemic therapies, including ≥ 1 anthracycline-based regimen.
  • Participant has demonstrated progressive disease on or after the last .
  • Participant is assessed as having at least one resectable lesion (or aggregate lesions) with an estimated minimum diameter of 1.5 cm (short axis) for lifileucel generation.
  • Following tumor resection for lifileucel generation, the participant will have at least one , as defined by v1.1 at Baseline.
  • Participant is expected to achieve washout from or anticancer therapy(ies).
  • If the participant has preplanned surgical procedure(s), the procedure will take place at least 14 days (for major operative procedures) prior to the tumor resection. Wound healing will have occurred, and all complications will have resolved at the time of tumor resection.
  • Participant has recovered from all prior anticancer treatment-related AEs to Grade ≤ 1(per ), except for peripheral neuropathy, alopecia, or vitiligo.
  • Participants of or those with partners of childbearing potential must be willing to practice an approved method of highly effective .
  • Participants must have adequate organ function.
  • Participant is willing to receive optimal supportive care, including intensive care, from enrollment until the first post-treatment tumor assessment.

Exclusion criteria

Exclusion Criteria:

  • Participant has symptomatic untreated .
  • The participant has an performance status of ≥ 2, a need for urgent therapy due to rapidly progressive disease or tumor mass effect, or an estimated of\< 6 months.
  • Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation.
  • Participant has any form of primary immunodeficiency (eg, severe combined immunodeficiency disease [SCID] or AIDS).
  • Participant has a history of to any component of the study intervention.
  • Participant had another primary within the previous 3 years (except for those that do not require treatment or have been curatively treated > 1 year ago, and in the judgment of the investigator does not pose a significant risk of recurrence.

Other protocol defined inclusion/exclusion criteria could apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Lifileucel

    Biological: Lifileucel

Interventions

  • BiologicalLifileucel

    Study intervention will begin with a tumor resection from which lifileucel will be generated. The lifileucel regimen consists of a preparative NMA-LD regimen (ie, cyclophosphamide with mesna followed by fludarabine), the lifileucel infusion, and an abbreviated course of aldesleukin (interleukin-2).

    Also known as: LN-145

07

What researchers measure

Primary outcomes

  1. Objective Response Rate

    To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the IRC

    Time frame: 5 years

Secondary outcomes

  1. Complete Response Rate

    To evaluate the efficacy of lifileucel as measured by CR rate per RECIST v1.1 as assessed by the IRC

    Time frame: 5 years

  2. Duration of Response

    To evaluate the efficacy of lifileucel as measured by DOR per RECIST v1.1 as assessed by the IRC

    Time frame: 5 years

  3. Disease Control Rate

    To evaluate the efficacy of lifileucel as measured by DCR per RECIST v1.1 as assessed by the IRC

    Time frame: 5 years

  4. Progression-Free Survival

    To evaluate the efficacy of lifileucel as measured by PFS per RECIST v1.1 as assessed by the IRC

    Time frame: 5 years

  5. Objective Response Rate

    To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the investigators

    Time frame: 5 years

  6. Complete Response Rate

    To evaluate the efficacy of lifileucel as measured CR rate per RECIST v1.1 as assessed by the investigators

    Time frame: 5 years

  7. Duration of Response

    To evaluate the efficacy of lifileucel as measured by DOR per RECIST v1.1 as assessed by the investigators

    Time frame: 5 years

  8. Disease Control Rate

    To evaluate the efficacy of lifileucel as measured by DCR per RECIST v1.1 as assessed by the investigators

    Time frame: 5 years

  9. Progression-Free Survival

    To evaluate the efficacy of lifileucel as measured by PFS per RECIST v1.1 as assessed by the investigators

    Time frame: 5 years

  10. Overall Survival

    To evaluate the efficacy of lifileucel as measured by OS

    Time frame: 5 years

  11. Adverse Events

    To evaluate safety and tolerability of lifileucel

    Time frame: 5 years

08

Study locations

2 of 2 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Sep 2033, 82 months after the start.

Of 35 phase 2 interventional studies under Liposarcoma, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 94. This study's planned 82 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Aug 3, 2026
StartActual
Oct 2, 2026was Sep 2026
Primary completionEst.
Sep 1, 2033
CompletionEst.
Sep 1, 2034
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
2 sites added — first site in United States
Show 2 added (2 United States)
  • Moffitt Cancer Center · Tampa, United States
  • Memorial Sloan Kettering Cancer Center · New York, United States
Oct 9, 2026
Start date
Sep 1, 2026→Oct 2, 2026 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in United States
    Show 2 added (2 United States)
    • Moffitt Cancer Center · Tampa, United States
    • Memorial Sloan Kettering Cancer Center · New York, United States
    Start date Sep 1, 2026→Oct 2, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07741877
Lead sponsor
Iovance Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Oct 2, 2026
Primary completion
Sep 1, 2033 (estimated)
Completion
Sep 1, 2034 (estimated)
Last update
Oct 9, 2026

Study contacts

Iovance Biotherapeutics Study Team
Contact
Clinical.Inquiries@iovance.com
844-845-4682

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lifileucel

Start the discussion